Greenwich LifeSciences Inc. has announced the ongoing global expansion of their Phase III FLAMINGO-01 trial, focusing on GLSI-100, a novel breast cancer vaccine immunotherapy. This trial is now active at over 120 sites across the United States and Europe. GLSI-100 combines the HER2-derived GP2 peptide with GM-CSF and aims to prevent breast cancer recurrences. In a prior Phase II trial, promising results were observed, showing no metastatic recurrences in immunized patients. The company has outlined a strategy to accelerate commercialization of GLSI-100, emphasizing advanced manufacturing readiness and strong academic partnerships. Results from the Phase III trial have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。